Formulations of growth hormone releasing factor (GRF) molecules with improved stability
View Patent ↗Stabilized solid and liquid pharmaceutical formulations comprising a GRF molecule as active ingredient, such as GRF analogs including those comprising an N-terminal-attached hydrophobic moiety, such as [trans-3-hexenoyl]hGHRH (1-44) amide, are disclosed. The formulation comprises a GRF molecule or a pharmaceutically acceptable salt thereof and a β-cyclodextrin which is not conjugated to the GRF molecule or salt thereof. Also disclosed is the use of the formulation for the treatment of various conditions, methods of preparing the formulation, as well as kits containing it. Methods of stabilizing (e.g., with respect to chemical stability) such GRF molecules, as well as methods of inhibiting their deamidation at Asn 8 , are also disclosed.
1. A liquid pharmaceutical formulation comprising:
[trans-3-hexenoyl]hGRF(1-44) amide (SEQ ID NO: 7) or a pharmaceutically acceptable salt thereof, in an amount of about 1 mg/ml to about 10 mg/ml; and
a modified β-cyclodextrin at a concentration of about 5% to about 10% (w/v),
wherein said formulation is isotonic and has a pH of about 5.5 to about 6.5, and wherein said modified β-cyclodextrin is not conjugated to said [trans-3-hexenoyl]hGRF(1-44) amide or pharmaceutically acceptable salt thereof.
2. The formulation of claim 1 , wherein the formulation has a tonicity of about 250 to about 350 mOsm/L.
3. The formulation of claim 1 , wherein the modified β-cyclodextrin is hydroxypropyl-β-cyclodextrin (HP-β-CD).
4. The formulation of claim 1 , wherein the modified β-cyclodextrin is methyl-β-cyclodextrin (M-β-CD).
5. The formulation of claim 1 , having a pH of about 5.8 to about 6.2.
6. The formulation of claim 1 , further comprising an anti-microbial agent.
7. The formulation of claim 6 , wherein the anti-microbial agent is m-cresol, benzyl alcohol, benzalkonium chloride, phenol or a combination thereof.
8. The formulation of claim 1 , wherein the [trans-3-hexenoyl]hGRF(1-44) amide or pharmaceutically acceptable salt thereof is present in an amount of about 4 to about 8 mg/ml.
9. The formulation of claim 8 , wherein the [trans-3-hexenoyl]hGRF(1-44) amide or pharmaceutically acceptable salt thereof is present in an amount of about 8 mg/ml.
10. The formulation of claim 1 , comprising:
about 4 to about 8 mg/mL of [trans-3-hexenoyl]hGRF(1-44) amide or a pharmaceutically acceptable salt thereof,
about 5 to about 10% (w/v) of a modified β-cyclodextrin, wherein the modified β-cyclodextrin is hydroxypropyl-β-cyclodextrin, methyl-β-cyclodextrin, or a combination thereof,
said formulation having a pH of about 5.5 to about 6.0.
11. The formulation of claim 10 , wherein the formulation has a tonicity of about 250 to about 350 mOsm/L.
12. The formulation of claim 10 , wherein at least 70% of the [trans-3-hexenoyl]hGHRH (1-44) amide or pharmaceutically acceptable salt thereof is not deamidated at Asn 8 after 2 years of storage at temperature conditions of about 2° C. to about 8° C.
13. The formulation of claim 12 , wherein at least 90% of the [trans-3-hexenoyl]hGHRH (1-44) amide or pharmaceutically acceptable salt thereof is not deamidated at Asn 8 after 2 years of storage at temperature conditions of about 2° C. to about 8° C.
14. A lyophilized or dehydrated pharmaceutical formulation prepared by lyophilizing or dehydrating the pharmaceutical formulation of claim 2 .
15. The lyophilized or dehydrated formulation of claim 14 , wherein at least 70% of the [trans-3-hexenoyl]hGRF (1-44) amide or pharmaceutically acceptable salt thereof is not deamidated at Asn 8 after 3 years of storage at temperature conditions of about 15° C. to about 25° C.
16. The lyophilized or dehydrated formulation of claim 15 , wherein at least 90% of the [trans-3-hexenoyl]hGRF (1-44) amide or pharmaceutically acceptable salt thereof is not deamidated at Asn 8 after 3 years of storage at temperature conditions of about 15° C. to about 25° C.
17. A method of stabilizing [trans-3-hexenoyl]hGRF (1-44) amide or a pharmaceutically acceptable salt thereof in a liquid pharmaceutical formulation, the method comprising combining the [trans-3-hexenoyl]hGRF (1-44) amide or pharmaceutically acceptable salt thereof in an amount of about 1 to about 10 mg/mL with a modified β-cyclodextrin at a concentration of about 5% to about 10% (w/v), wherein the modified β-cyclodextrin is not conjugated to the [trans-3-hexenoyl]hGRF (1-44) amide or pharmaceutically acceptable salt thereof, and wherein the formulation is isotonic and has a pH of about 5.5 to about 6.5.
18. The method of claim 17 , comprising:
(a) combining the [trans-3-hexenoyl]hGRF (1-44) amide or pharmaceutically acceptable salt thereof with the modified β-cyclodextrin in an aqueous solution, wherein the modified β-cyclodextrin is not conjugated to the [trans-3-hexenoyl]hGRF (1-44) amide or pharmaceutically acceptable salt thereof;
(b) adjusting the pH of the solution to about 5.5 to about 6.5; and
(c) lyophilizing or dehydrating the solution.
19. A method of inhibiting Asn 8 deamidation of [trans-3-hexenoyl]hGRF (1-44) amide or a pharmaceutically acceptable salt thereof in a liquid pharmaceutical formulation, the method comprising combining the [trans-3-hexenoyl]hGRF (1-44) amide or pharmaceutically acceptable salt thereof in an amount of about 1 to about 10 mg/mL with a modified β-cyclodextrin at a concentration of about 5% to about 10% (w/v), wherein the modified β-cyclodextrin is not conjugated to the GRF molecule or pharmaceutically acceptable salt thereof, and wherein the formulation is isotonic and has a pH of about 5.5 to about 6.5.
20. The method of claim 19 , comprising:
(a) combining the [trans-3-hexenoyl]hGRF (1-44) amide or pharmaceutically acceptable salt thereof with the modified β-cyclodextrin in an aqueous solution, wherein the modified β-cyclodextrin is not conjugated to the [trans-3-hexenoyl]hGRF (1-44) amide or pharmaceutically acceptable salt thereof; and
(b) adjusting the pH of the solution to about 5.5 to about 6.5.
21. The method of claim 20 , further comprising lyophilizing or dehydrating the solution after step (b).
22. The method of claim 19 , wherein the modified β-cyclodextrin is hydroxypropyl-β-cyclodextrin (HP-β-CD), methyl-β-cyclodextrin (M-β-CD), or a combination thereof.
23. A suspension obtained by reconstituting the lyophilized or dehydrated pharmaceutical formulation of claim 14 with a suitable aqueous solution.